Recent Updates
Recently added Catalysts
IMMP

Prima BioMed Appoints Non-Executive Director to the Board

Key Takeaway: Prima BioMed Appoints Non-Executive Director to the Board

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Full Press Release Details

Prima BioMed Appoints Non-Executive Director to the Board.
Last updated: Aug 19, 2017